The global chemotherapy-induced nausea and vomiting (CINV) drugs market is likely to reach value at US$ 2,558.12 million in 2023 and is expected to reach US$ 4,672.82 million by 2030, growing at a CAGR of 6.6% from 2023 to 2030.

Chemotherapy-induced nausea and vomiting (CINV) is a common and debilitating side effect of cancer treatment. It can significantly impact a patient's quality of life and adherence to chemotherapy. The global Chemotherapy-induced nausea and vomiting drugs market is projected to witness significant growth in the coming years, driven by the increasing prevalence of cancer, rising demand for effective Chemotherapy-induced nausea and vomiting control, and advancements in drug development.

Get Recently Updated Report of Market as Sample Copy! https://absolutemarketresearch.com/Global-Chemotherapy-Induced-Nausea-and-Vomiting-(CINV)-Drugs-Market/1230/request-sample

Chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

Types of Chemotherapy-induced nausea and vomiting Drugs:

Chemotherapy-induced nausea and vomiting drugs can be broadly classified into three main categories:

1.    5-HT3 Receptor Antagonists: These drugs block the action of serotonin, a neurotransmitter involved in nausea and vomiting. Examples include ondansetron (Zofran), granisetron (Kytril), dolasetron (Anzemet), and palonosetron (Aloxi).

2.    NK1 Receptor Antagonists: These drugs block the action of substance P, another neurotransmitter involved in nausea and vomiting. Examples include aprepitant (Emend) and fosaprepitant (Apreva).

3.    Corticosteroids: These drugs have anti-inflammatory and antiemetic properties. Dexamethasone is the most commonly used corticosteroid for Chemotherapy-induced nausea and vomiting.

Choosing the Right Chemotherapy-induced nausea and vomiting Drugs:

The choice of Chemotherapy-induced nausea and vomiting drugs depends on several factors, including the type of chemotherapy, the patient's risk of Chemotherapy-induced nausea and vomiting, and any other medical conditions the patient may have.

For patients receiving highly emetogenic chemotherapy (HEC), which has the highest risk of causing CINV, a combination of a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and dexamethasone is recommended. For patients receiving moderately emetogenic chemotherapy (MEC), a 5-HT3 receptor antagonist with dexamethasone is usually sufficient. For patients receiving low-emetogenic chemotherapy, dexamethasone alone may be enough.

Side Effects of Chemotherapy-induced nausea and vomiting Drugs:

Chemotherapy-induced nausea and vomiting drugs are generally well-tolerated, but they can cause side effects such as headache, constipation, and fatigue. Some drugs, such as aprepitant, can also cause dizziness and vertigo.

Overall, Chemotherapy-induced nausea and vomiting drugs play an important role in improving the quality of life for cancer patients and helping them continue their chemotherapy treatment.

Key Market Drivers:

• Rising Prevalence of Cancer: The increasing incidence of cancer is a major driver of the Chemotherapy-induced nausea and vomiting drugs market. As the global cancer burden continues to grow, the demand for effective Chemotherapy-induced nausea and vomiting control measures is expected to rise.
• Demand for Effective CINV Control: Chemotherapy-induced nausea and vomiting can significantly impair a patient's quality of life and adherence to chemotherapy. The growing demand for effective Chemotherapy-induced nausea and vomiting control measures is driving the development of new and more potent drugs.
• Advancements in Drug Development: Continuous advancements in drug development are leading to the introduction of novel and more targeted Chemotherapy-induced nausea and vomiting drugs. These drugs offer improved efficacy and reduced side effects compared to traditional treatments.

Key Takeaways:

• The global Chemotherapy-induced nausea and vomiting (CINV) drugs market is likely to reach value at US$ 2,558.12 million in 2023 and is expected to reach US$ 4,672.82 million by 2030, growing at a CAGR of 6.6% from 2023 to 2030.
• The growth of the market is driven by the increasing prevalence of cancer, the rising adoption of chemotherapy, and the growing demand for effective Chemotherapy-induced nausea and vomiting prophylaxis and treatment.
• The acute emesis segment is expected to dominate the market due to the advancement in chemotherapy and the increasing use of highly emetogenic chemotherapy (HEC) drugs.
• North America is expected to hold the largest market share due to the high prevalence of cancer, the early adoption of new technologies, and the strong presence of key players in the region.

Regional Outlook:

• North America is expected to hold the largest market share, accounting for approximately 38% of the global market in 2030.
• Europe is expected to be the second-largest market, followed by Asia Pacific.
• The growth in the Asia Pacific market is expected to be driven by the increasing prevalence of cancer, the growing demand for affordable Chemotherapy-induced nausea and vomiting drugs, and the expanding healthcare infrastructure in the region.

Key Players:

• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis AG
• Sanofi SA
• Merck & Co., Inc.
• Eisai Co., Ltd.
• AstraZeneca plc
• Daiichi Sankyo Co., Ltd.
• Cosmo Pharmaceuticals Ltd.
• Heron Therapeutics, Inc.

Segmentation:

By Product:

• 5-HT3 antagonists
• NK1 receptor antagonists
• Steroids
• Antiemetics
• Others

By End User:

• Hospitals
• Cancer centers
• Ambulatory care centers
• Others

By Type:

• Acute emesis
• Delayed emesis
• Breakthrough emesis